Payment overview · 2025
General Payments
$105.13
5 reported records · 5 companies
Healthcare provider profile · identity verified
Chris Patrick Doerr, APN
Physician Assistants & Advanced Practice Nursing Providers|Clinical Nurse Specialist|Psychiatric/Mental Health, Adult · PARAMUS, NJ · NPI 1003990771
Verified facts
What the public records show
CMS Open Payments records show Chris Patrick Doerr, APN received $105.13 in general payments during 2025 across 5 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 22.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Invega Sustenna.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Lybalvi by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Invega Sustenna by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Abilify Maintena by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $23.72 | 22.6% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $22.99 | 21.9% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $21.26 | 20.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.95 | 18.0% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $18.21 | 17.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $105.13 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $23.72 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $22.99 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA INITIO Normalized: aristada initio |
Drug | Alkermes, Inc. | $22.99 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $21.26 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.95 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $18.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INVEGA SUSTENNA invega sustenna |
2025 | Invega Sustenna | 2024 | 190 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | LYBALVI open payments reported associated product |
CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566 |
Lybalvi · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
190 | 17 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clozapine | Clozapine | 497 | 25 |
| Olanzapine | Olanzapine | 358 | 32 |
| Clonazepam | Clonazepam | 317 | 31 |
| Benztropine Mesylate | Benztropine Mesylate | 272 | 28 |
| Paroxetine Hcl | Paroxetine Hcl | 195 | 18 |
| Invega Sustenna | Paliperidone Palmitate | 190 | 17 |
| Risperidone | Risperidone | 164 | 14 |
| Aripiprazole | Aripiprazole | 150 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 120 | suppressed |
| Lorazepam | Lorazepam | 117 | 17 |
| Divalproex Sodium Er | Divalproex Sodium | 112 | 12 |
| Sertraline Hcl | Sertraline Hcl | 111 | 12 |
| Divalproex Sodium | Divalproex Sodium | 102 | 12 |
| Haloperidol | Haloperidol | 100 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 11 |
| Olanzapine Odt | Olanzapine | 85 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 84 | 11 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 75 | suppressed |
| Gabapentin | Gabapentin | 63 | suppressed |
| Lamotrigine | Lamotrigine | 63 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 60 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 60 | suppressed |
| Bupropion Xl | Bupropion Hcl | 54 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 54 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 52 | suppressed |
| Clozaril | Clozapine | 48 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 42 | suppressed |
| Abilify Maintena | Aripiprazole | 39 | suppressed |
| Topiramate | Topiramate | 38 | suppressed |
| Mirtazapine | Mirtazapine | 36 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Perphenazine | Perphenazine | 33 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Carbamazepine | Carbamazepine | 26 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Lybalvi | Olanzapine/Samidorphan Malate | 25 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 25 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 23 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 20 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 20 | suppressed |
| Clozapine Odt | Clozapine | 19 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 18 | suppressed |
| Fluphenazine Decanoate | Fluphenazine Decanoate | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Zoloft | Sertraline Hcl | 12 | suppressed |
| Zyprexa | Olanzapine | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $105.13 · 5 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ARISTADA, ARISTADA INITIO, CAPLYTA, INGREZZA, INVEGA SUSTENNA, REXULTI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Invega Sustenna play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Alkermes, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error